GoodRx stock surges as company discusses TrumpRx role with administration

Published 09/10/2025, 17:50
© Reuters.

Investing.com -- GoodRx Holdings (NASDAQ:GDRX) stock surged 18% after reports emerged that the prescription drug savings platform is in discussions with the Trump administration about participating in the upcoming TrumpRx website initiative.

The company is among several retail pharmacies engaging with the administration about potential involvement in TrumpRx, according to Reuters. This suggests the platform may expand beyond its initially described purpose of connecting consumers to pharmaceutical companies’ direct discount programs.

TrumpRx, scheduled to launch next year, aims to provide consumers access to medications at discounted prices. The initiative was announced at a recent White House event, where President Donald Trump and health officials presented it as a way for Americans to obtain drugs at lower costs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.